Health and Fitness Health and Fitness
Thu, August 9, 2012
Wed, August 8, 2012
Tue, August 7, 2012
Mon, August 6, 2012
Fri, August 3, 2012
Thu, August 2, 2012
[ Thu, Aug 02nd 2012 ] - Market Wire
00 p.m. EDT
Wed, August 1, 2012
[ Wed, Aug 01st 2012 ] - Market Wire
Head of European Operations
Tue, July 31, 2012
Mon, July 30, 2012
Sun, July 29, 2012
Fri, July 27, 2012
Thu, July 26, 2012
Wed, July 25, 2012
Tue, July 24, 2012
[ Tue, Jul 24th 2012 ] - Market Wire
Neogen reports year end results
Mon, July 23, 2012
Sun, July 22, 2012
Sat, July 21, 2012
Fri, July 20, 2012
Thu, July 19, 2012
Wed, July 18, 2012
Tue, July 17, 2012
Mon, July 16, 2012

Equity Research on Forest Laboratories Inc. and Endo Health Solutions Inc. - Patent Expiries and New Releases Lead to Mixed Res


//health-fitness.news-articles.net/content/2012/ .. expiries-and-new-releases-lead-to-mixed-res.html
Published in Health and Fitness on Monday, July 30th 2012 at 5:36 GMT by Market Wire   Print publication without navigation


July 30, 2012 08:20 ET

Equity Research on Forest Laboratories Inc. and Endo Health Solutions Inc. - Patent Expiries and New Releases Lead to Mixed Results for Drug Manufacturers

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Jul 30, 2012) -  [ www.StockCall.com ] offers free research on Forest Laboratories Inc. (NYSE: [ FRX ]) and Endo Health Solutions Inc. (NASDAQ: [ ENDP ]) from the Drug Manufacturers - Other industry. Access these reports by clicking on the links below or by copy and pasting those to your address bar.

[ www.StockCall.com/reports ]

The drug manufacturers industry, which features companies such as Forest Laboratories Inc. and Endo Health Solutions Inc. continues to be negatively impacted by patent expirations. Several major brand-name drugs have lost exclusivity as of late, and the results are appearing on company financials.

StockCall.com is an online platform where investors doing their due-diligence on the Drug Manufacturers - Other industry can have easy and free access to our analyst research and opinions on Forest Laboratories Inc. and Endo Health Solutions Inc. To see how companies in this industry have grown over the past years and how they are expected to perform in the future, please visit the link below.

[ www.StockCall.com ]

In the case of Forest Laboratories, the company recently reported that earnings from its fiscal 1st quarter came in at $55.3 million, down substantially from earnings of $258.1 million achieved during the same quarter last year. One reason for the decline was the loss of exclusivity for Lexapro. Endo Health has also been dealing with challenges stemming from losses of exclusivity. Register now to have free access to our report on Endo Health Solutions Inc., and to do so please click the link below.

[ www.StockCall.com/ENDP300712.pdf ]

In an attempt to improve sales and grow revenues, companies in the industry have been working hard on releasing new products. Forest Laboratories together with Almirall S.A. have recently had success in this regard, stating that the FDA has approved Tudorza™ Pressair™ for the treatment of Bronchospasm associated with chronic obstructive pulmonary disease. Investors and shareholders of Forest Laboratories Inc. can simply register for our complimentary reports by clicking on the link below.

[ www.StockCall.com/FRX300712.pdf ]

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.



Publication Contributing Sources